Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults

Infections, Streptococcal Clinical Trial

Official title:

A Study to Evaluate Safety and Immunogenicity of a Booster Dose of Two Formulations of GSK Biologicals' Pneumococcal Candidate Vaccine in Healthy Young Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00896064
• Other study ID #: 112993
• Status: Completed
• Phase: Phase 2
• Start date: May 18, 2009
• Est. completion date: August 5, 2009

Study information

• Verified date: April 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of a booster dose of pneumococcal vaccines (GSK 2189242A) in young adults.

This protocol posting deals with objectives & outcome measures of the booster phase. The objectives & outcome measures of the primary phase are presented in a separate protocol posting (NCT 00707798)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: August 5, 2009
• Est. primary completion date: August 5, 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 41 Years

Eligibility

Inclusion Criteria:

• Subjects who the investigator believes will comply with the requirements of the protocol should be enrolled in the study.

• A male or female between, and including, 18 and 41 years old at the time of vaccination.

• Subjects who previously participated in the study NCT00707798 and received one of the two investigational GSK2189242A vaccine formulations during the primary study.

• Written informed consent obtained from the subject.

• Free of obvious health problems as established by medical history, clinical examination and clinical laboratory assessment before entering into the study.

• Female subjects of non-childbearing potential (defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause) may be enrolled in the study.

• Female subjects of childbearing potential may be enrolled in the study, if the subject:

• has practiced adequate contraception for 30 days prior to vaccination, and

• has a negative pregnancy test on the day of vaccination, and

• has agreed to continue adequate contraception during the entire treatment period and for 2 months after vaccination.

Exclusion Criteria:

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the vaccination, or planned use during the study period.

• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to vaccination.

• Planned administration/administration of a vaccine not foreseen by the study protocol during the period starting 30 days prior to the vaccination and ending one month (minimum 30 days) after vaccination.

• Administration of any pneumococcal vaccine other than the study vaccine during the period between end of study NCT00707798 and study vaccination.

• Bacterial pneumonia within the period between end of study NCT00707798 and study vaccination.

• Invasive pneumococcal disease (IPD) within the period between end of study NCT00707798 and study vaccination.

• Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection (no laboratory testing required).

• History of thrombocytopenia or bleeding disorder.

• Anaphylactic reaction following the previous administration of the vaccine or history of reactions or allergic disease likely to be exacerbated by any component of the vaccine.

• Current serious neurologic or mental disorders.

• Inflammatory processes such as known chronic active infections (e.g. Hepatitis B, C).

• All past or current malignancies (excluding non-melanic skin cancer) and lymphoproliferative disorders.

• Acute disease at the time of enrolment/vaccination.

• Fever at the time of vaccination. Fever is defined as temperature >= 37.5°C on oral setting.

• Physical examination positive for acrocyanosis, jaundice, splenomegaly.

• Acute or chronic, clinically significant anaemia, pulmonary, cardiovascular, hematologic, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests, at the discretion of the investigator

• Administration of immunoglobulins and/or any blood products within the three months preceding vaccination or planned administration during the study period.

• Pregnant or lactating female.

• Female planning to become pregnant or planning to discontinue contraceptive precautions.

• History of chronic alcohol consumption and/or drug abuse.

• Other conditions that the principal investigator judges may interfere with study findings.

Related Conditions & MeSH terms

• Infections, Streptococcal
• Streptococcal Infections

Intervention

Biological:
• Pneumococcal vaccine GSK2189242A (formulation 1)
One dose will be administered intramuscularly at Study Day 0.
• Pneumococcal vaccine GSK2189242A (formulation 2)
One dose will be administered intramuscularly at Study Day 0.

Locations

Country	Name	City	State
Belgium	GSK Investigational Site	Gent

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects With Grade 3 Solicited Local Symptoms	Assessed solicited local symptoms were pain, redness and swelling. Grade 3 pain = significant pain at rest, pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.	During the 7-day (Days 0-6) post-booster vaccination period
Primary	Number of Subjects With Grade 3 and Vaccine-related Solicited General Symptoms	Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), headache, malaise, myalgia and fever [defined as oral temperature equal to or above (=) 37.5 degrees Celsius (°C)]. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.5 °C. Related = general symptom assessed by the investigator to be casually related to the study vaccination.	During the 7-day (Days 0-6) post-booster vaccination period
Primary	Number of Subjects With Grade 3 and Vaccine-related Unsolicited Adverse Events (AEs)	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.	During the 31-day (Days 0-30) post-booster vaccination period
Primary	Number of Subjects With Any Vaccine-related Serious Adverse Events (SAEs)	SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.	During the entire study period (from Day 0 to Day 30)
Primary	Number of Subjects With Grade 3 Haematological or Biochemical Abnormalities	Among haematological or biochemical abnormalities assessed were: Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Cholesterol, Creatine Phosphokinase (CRP), Hemoglobin decrease, Haemoglobin, Lactate dehydrogenase (LDH), Neutrophils, Red blood cells (RBC), Reticulocytes, White blood cells (WBC) and Overall parameters.; Assessment of intensity: Grading of the haematological and biochemical parameters was performed using the standard Food and Drug Administration (FDA) Toxicity Grading Scale. Changes compared to normal reference ranges were graded: Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening	At Days 1 and 6 post-booster vaccination
Secondary	Antibody Concentrations Against Pneumococcal Pneumolysin Toxoid (dPly) and Histidine Triad Protein D (PhtD) Proteins	Anti-dPly and anti-PhtD antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in LU/mL. The reference seropositivity cut-off values were equal to or above (=) 599 LU/mL for anti-dPly and = 391 LU/mL for anti-PhtD.	Prior to the booster vaccination (Day 0) and one month post-booster vaccination (Day 30)
Secondary	Titers for Antibodies Against Pneumolysin Haemolysis (Hem-dPly) Protein	Antibody titers are presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (=) 6.	Prior to the booster vaccination (Day 0) and one month post-booster vaccination (Day 30)
Secondary	Number of Subjects With Any Solicited Local Symptoms	Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.	During the 7-day (Days 0-6) post-booster vaccination period
Secondary	Number of Subjects With Any Solicited General Symptoms	Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), headache, malaise, myalgia and fever [defined as oral temperature equal to or above (=) 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade.	During the 7-day (Days 0-6) post-booster vaccination period
Secondary	Number of Subjects With Any Unsolicited AEs	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.	During the 31-day (Days 0-30) post-booster vaccination period
Secondary	Number of Subjects With Any SAEs	SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.	During the entire study period (from Day 0 to Day 30)
Secondary	Number of Subjects With Grade 1, Grade 2 and Grade 4 Haematological or Biochemical Abnormalities	Among haematological or biochemical abnormalities assessed were: Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Cholesterol, Creatine Phosphokinase (CRP), Hemoglobin decrease, Haemoglobin, Lactate dehydrogenase (LDH), Neutrophils, Red blood cells (RBC), Reticulocytes, White blood cells (WBC) and Overall parameters.; Assessment of intensity: Grading of the haematological and biochemical parameters was performed using the standard Food and Drug Administration (FDA) Toxicity Grading Scale. Changes compared to normal reference ranges were graded: Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening	At 1 and 6 days post-booster vaccination

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.